London-based Perceptic has emerged from stealth with a $12M seed round led by Accel to build a single AI platform that follows a drug from early discovery through clinical development, a workflow currently handled by disconnected systems across most pharma companies.
The founders built Palantir’s AIP product and its Life Sciences practice, and already have paid production deployments running across multiple top-tier pharma companies including CSL.
The global AI in drug discovery market stood at $1.72B in 2024 and is projected to surpass $8.5B by 2030, growing at over 30% annually.
A drug approved today took more than a decade to reach patients and cost upwards of $2 billion to develop. It also ran on fragmented systems that barely communicate with each other – research insights disappearing between teams, clinical data sitting in disconnected silos, and billion-dollar decisions depending on manually stitching together incomplete information. Three people who spent years inside Palantir building production AI for the world’s most complex enterprises decided that was the problem worth solving.
Perceptic, founded in London in 2024 by Tilman Flock, Martin Copes, and Zaki Trache, has emerged from stealth with a $12M seed round led by Accel, alongside Air Street Capital and Elder Gull. All three founders were key engineers on Palantir’s AIP product and central to shaping its Life Sciences practice, a pedigree that has become a reliable signal for investors backing enterprise AI spinouts. The company employs around 20 people.
